SCHEMBL3260481

SCHEMBL3260481

Cn1ccc(C(=O)O)c1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 1/20 0.45
NOTUM Q6P988 2/20 0.44
ALDH1A1 P00352 2/20 0.43
ALOX15 P16050 1/20 0.43
DHODH Q02127 1/20 0.42
MMP1 P03956 1/20 0.40
MMP7 P09237 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MMP13 P45452 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HNF4A P41235 3/20 0.39
ACMSD Q8TDX5 2/20 0.39
DHFR P00374 1/20 0.39
MCL1 Q07820 1/20 0.39
CDC25B P30305 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27633481 0.89 LIPG (0.42) LIPGNOTUMALDH1A1DHODHMMP1
SCHEMBL34469884 0.84 PTGS2 (0.48) LIPGNOTUMALDH1A1DHODHCYP1A2
SCHEMBL3493724 0.77 NOTUM (0.49) NOTUMALDH1A1ALOX15MAOAMAOB
SCHEMBL3264188 0.77 NOTUM (0.41) NOTUMALDH1A1ALOX15DHODHMAOA
SCHEMBL3491824 0.76 NOTUM (0.61) NOTUMALDH1A1ALOX15DHODHMAOA
SCHEMBL14263093 0.75 TRPV1 (0.44) LIPGALDH1A1CYP1A2
SCHEMBL27562523 0.75 NOTUM (0.44) NOTUMALDH1A1CYP2C9KDM4E
SCHEMBL3494668 0.74 MAOA (0.41) ALDH1A1ALOX15DHODHMAOAMAOB
SCHEMBL30740984 0.74 HTR2C (0.45) NOTUMALDH1A1CYP1A2ATMKDM4E
SCHEMBL3496060 0.72 NOTUM (0.64) NOTUMALDH1A1KDM4ELMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7671049-B2 Pyrrole based inhibitors of glycogen synthase kinase 3 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-03-02 US disclosed
US-20070244109-A1 PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-10-18 US disclosed
US-7250443-B2 Pyrrole based inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2007-07-31 US disclosed
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AHR, ARNT, MYC LIPG 2715/4885NOTUM 3896/4885ALDH1A1 240/4885
US-20070244109-A1 PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 GSK3B, GSK3A, PYGB LIPG 756/4885NOTUM 731/4885ALDH1A1 3907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.